JPH08507507A - 神経−aidsの治療におけるリルゾールの適応 - Google Patents
神経−aidsの治療におけるリルゾールの適応Info
- Publication number
- JPH08507507A JPH08507507A JP6519647A JP51964794A JPH08507507A JP H08507507 A JPH08507507 A JP H08507507A JP 6519647 A JP6519647 A JP 6519647A JP 51964794 A JP51964794 A JP 51964794A JP H08507507 A JPH08507507 A JP H08507507A
- Authority
- JP
- Japan
- Prior art keywords
- riluzole
- treatment
- neuro
- pharmaceutically acceptable
- aids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.リルゾールもしくはその化合物の薬剤学的に許容される塩の、神経−AI DSの治療を意図する医薬製品の調製への適応。 2.HIV−1ウイルスに関連する痴呆、認識障害、神経障害、筋障害、眼科 的疾患、および全ての神経学的症状に関わる疾患の治療を意図する医薬製品の調 製のための、請求の範囲1に記載の適応。 3.25〜200mgのリルゾールを含む医薬製品を取得するための、請求の 範囲1に記載の適応。 4.リルゾールもしくはその化合物の薬剤学的に許容される塩を(一つ/複数 )、一つもしくは複数の適合的かつ薬剤学的に許容される賦形剤および/または 補助剤と混合することを特徴とする、神経−AIDSの治療に有用な医薬製品を 調製するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9302568A FR2702148B1 (fr) | 1993-03-05 | 1993-03-05 | Application d'anticonvulsivants dans le traitement du neuro-sida. |
FR93/02568 | 1993-03-05 | ||
PCT/FR1994/000208 WO1994020103A1 (fr) | 1993-03-05 | 1994-02-25 | Application du riluzole dans le traitement du neuro-sida |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08507507A true JPH08507507A (ja) | 1996-08-13 |
JP3578174B2 JP3578174B2 (ja) | 2004-10-20 |
Family
ID=9444690
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6519648A Pending JPH08507508A (ja) | 1993-03-05 | 1994-02-25 | 神経−aidsの治療におけるカルバマゼピンおよびオキシカルバゼピンのような鎮痙薬の適応 |
JP51964794A Expired - Fee Related JP3578174B2 (ja) | 1993-03-05 | 1994-02-25 | 神経−aidsの治療におけるリルゾールの適応 |
JP6519649A Pending JPH08507509A (ja) | 1993-03-05 | 1994-02-25 | 神経−aidsの治療におけるラモトリギンの適応 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6519648A Pending JPH08507508A (ja) | 1993-03-05 | 1994-02-25 | 神経−aidsの治療におけるカルバマゼピンおよびオキシカルバゼピンのような鎮痙薬の適応 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6519649A Pending JPH08507509A (ja) | 1993-03-05 | 1994-02-25 | 神経−aidsの治療におけるラモトリギンの適応 |
Country Status (23)
Country | Link |
---|---|
US (2) | US5629312A (ja) |
EP (3) | EP0687177B1 (ja) |
JP (3) | JPH08507508A (ja) |
KR (3) | KR960700721A (ja) |
AT (2) | ATE201597T1 (ja) |
AU (3) | AU675119B2 (ja) |
CA (3) | CA2154572C (ja) |
CZ (3) | CZ285339B6 (ja) |
DE (2) | DE69401577T2 (ja) |
DK (2) | DK0687176T3 (ja) |
ES (2) | ES2096455T3 (ja) |
FR (1) | FR2702148B1 (ja) |
GR (2) | GR3022356T3 (ja) |
HU (3) | HU217132B (ja) |
IL (3) | IL108844A (ja) |
NO (3) | NO307687B1 (ja) |
PL (3) | PL310476A1 (ja) |
PT (1) | PT687176E (ja) |
RU (1) | RU2157205C2 (ja) |
SK (3) | SK107595A3 (ja) |
UA (1) | UA41355C2 (ja) |
WO (3) | WO1994020103A1 (ja) |
ZA (2) | ZA941530B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003514858A (ja) * | 1999-11-24 | 2003-04-22 | アベンテイス・フアルマ・ソシエテ・アノニム | リルゾールおよびギャバペンチンの組み合わせ剤ならびに医薬としてのその使用 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866597A (en) * | 1993-03-19 | 1999-02-02 | Glaxo Wellcome Inc. | Use of triazine compounds for the treatment of memory and learning disorders |
GB9424766D0 (en) * | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
DE19603984A1 (de) * | 1996-02-05 | 1997-08-07 | Bayer Ag | Granulate von Triazinen |
US20020022056A1 (en) | 1997-02-14 | 2002-02-21 | Burkhard Schlutermann | Oxacarbazepine film-coated tablets |
CO4920215A1 (es) * | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
US5922746A (en) * | 1997-03-27 | 1999-07-13 | Allergan | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
GB9721497D0 (en) * | 1997-10-09 | 1997-12-10 | Ciba Geigy Ag | Organic compounds |
FR2774592B1 (fr) * | 1998-02-06 | 2000-03-17 | Rhone Poulenc Rorer Sa | Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet |
FR2774908B1 (fr) * | 1998-02-17 | 2000-06-23 | Centre Nat Rech Scient | Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne |
FR2787028B1 (fr) | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
EP1173175A1 (en) * | 1999-04-29 | 2002-01-23 | Centre National De La Recherche Scientifique (Cnrs) | A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping |
US7479498B2 (en) * | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
GB9930058D0 (en) | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
US6207179B1 (en) * | 2000-05-18 | 2001-03-27 | Phoenix Scientific, Inc. | Parasiticidal formulation for animals and a method of making this formulation |
CA2471666C (en) | 2004-06-18 | 2009-10-13 | Apotex Pharmachem Inc. | An improved process for the preparation of oxcarbazepine and related intermediates |
EP3753561A1 (en) * | 2005-04-05 | 2020-12-23 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
US20060252745A1 (en) * | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
FR2910811B1 (fr) * | 2007-01-03 | 2009-07-10 | Ass Pour Le Dev De La Biothera | Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments |
GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
CN107249567B (zh) * | 2014-11-21 | 2021-08-03 | 拜尔哈文制药股份有限公司 | 利鲁唑的舌下给药 |
KR20240029730A (ko) * | 2021-02-24 | 2024-03-06 | 브이지피 아이피씨오 엘엘씨 | 증발기 코일용 발포 세정제 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
US4431641A (en) * | 1980-10-17 | 1984-02-14 | Ciba-Geigy Corporation | Pharmaceutical compositions having antiepileptic and antineuralgic action |
GB8613183D0 (en) * | 1986-05-30 | 1986-07-02 | Wellcome Found | Triazine salt |
US4826860A (en) * | 1987-03-16 | 1989-05-02 | Warner-Lambert Company | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents |
US4918090A (en) * | 1988-01-25 | 1990-04-17 | Warner-Lambert Company | Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents |
EP0435826A1 (de) * | 1989-12-27 | 1991-07-03 | Ciba-Geigy Ag | Intravenöse Lösungen für Status Epilepticus |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
JPH07308499A (ja) * | 1994-05-20 | 1995-11-28 | Brother Ind Ltd | 衣類乾燥機 |
-
1993
- 1993-03-05 FR FR9302568A patent/FR2702148B1/fr not_active Expired - Lifetime
-
1994
- 1994-02-25 AT AT94908374T patent/ATE201597T1/de active
- 1994-02-25 KR KR1019950703734A patent/KR960700721A/ko not_active Application Discontinuation
- 1994-02-25 WO PCT/FR1994/000208 patent/WO1994020103A1/fr active IP Right Grant
- 1994-02-25 DE DE69401577T patent/DE69401577T2/de not_active Expired - Fee Related
- 1994-02-25 PL PL94310476A patent/PL310476A1/xx unknown
- 1994-02-25 JP JP6519648A patent/JPH08507508A/ja active Pending
- 1994-02-25 HU HU9502585A patent/HU217132B/hu not_active IP Right Cessation
- 1994-02-25 DE DE69427344T patent/DE69427344T2/de not_active Expired - Lifetime
- 1994-02-25 KR KR1019950703733A patent/KR960700723A/ko not_active Application Discontinuation
- 1994-02-25 SK SK1075-95A patent/SK107595A3/sk unknown
- 1994-02-25 HU HU9502583A patent/HUT73434A/hu unknown
- 1994-02-25 AU AU61439/94A patent/AU675119B2/en not_active Ceased
- 1994-02-25 PL PL94310474A patent/PL310474A1/xx unknown
- 1994-02-25 AU AU61438/94A patent/AU6143894A/en not_active Abandoned
- 1994-02-25 ES ES94908376T patent/ES2096455T3/es not_active Expired - Lifetime
- 1994-02-25 CA CA002154572A patent/CA2154572C/fr not_active Expired - Fee Related
- 1994-02-25 CZ CZ952259A patent/CZ285339B6/cs not_active IP Right Cessation
- 1994-02-25 JP JP51964794A patent/JP3578174B2/ja not_active Expired - Fee Related
- 1994-02-25 AU AU61437/94A patent/AU675118B2/en not_active Ceased
- 1994-02-25 CZ CZ952260A patent/CZ226095A3/cs unknown
- 1994-02-25 SK SK1076-95A patent/SK279659B6/sk not_active IP Right Cessation
- 1994-02-25 RU RU95121731/14A patent/RU2157205C2/ru not_active IP Right Cessation
- 1994-02-25 DK DK94908374T patent/DK0687176T3/da active
- 1994-02-25 AT AT94908376T patent/ATE147981T1/de active
- 1994-02-25 PL PL94310475A patent/PL310475A1/xx unknown
- 1994-02-25 CA CA002154573A patent/CA2154573A1/fr not_active Abandoned
- 1994-02-25 UA UA95083996A patent/UA41355C2/uk unknown
- 1994-02-25 WO PCT/FR1994/000209 patent/WO1994020110A1/fr not_active Application Discontinuation
- 1994-02-25 CZ CZ952261A patent/CZ284423B6/cs unknown
- 1994-02-25 PT PT94908374T patent/PT687176E/pt unknown
- 1994-02-25 HU HU9502584A patent/HU9502584D0/hu unknown
- 1994-02-25 CA CA002154571A patent/CA2154571A1/fr not_active Abandoned
- 1994-02-25 EP EP94908376A patent/EP0687177B1/fr not_active Expired - Lifetime
- 1994-02-25 US US08/530,253 patent/US5629312A/en not_active Expired - Fee Related
- 1994-02-25 EP EP94908374A patent/EP0687176B1/fr not_active Expired - Lifetime
- 1994-02-25 JP JP6519649A patent/JPH08507509A/ja active Pending
- 1994-02-25 DK DK94908376.0T patent/DK0687177T3/da active
- 1994-02-25 ES ES94908374T patent/ES2157252T3/es not_active Expired - Lifetime
- 1994-02-25 KR KR1019950703732A patent/KR100318168B1/ko not_active IP Right Cessation
- 1994-02-25 EP EP94908375A patent/EP0687179A1/fr not_active Withdrawn
- 1994-02-25 SK SK1074-95A patent/SK107495A3/sk unknown
- 1994-02-25 WO PCT/FR1994/000210 patent/WO1994020108A1/fr active IP Right Grant
- 1994-03-03 IL IL108844A patent/IL108844A/en not_active IP Right Cessation
- 1994-03-03 IL IL10884694A patent/IL108846A0/xx not_active IP Right Cessation
- 1994-03-03 IL IL10884594A patent/IL108845A0/xx unknown
- 1994-03-04 ZA ZA941530A patent/ZA941530B/xx unknown
- 1994-03-04 ZA ZA941525A patent/ZA941525B/xx unknown
-
1995
- 1995-02-28 US US08/396,106 patent/US5624945A/en not_active Expired - Lifetime
- 1995-08-28 NO NO953370A patent/NO307687B1/no not_active IP Right Cessation
- 1995-08-28 NO NO953372A patent/NO953372L/no unknown
- 1995-08-28 NO NO953371A patent/NO953371L/no unknown
-
1997
- 1997-01-23 GR GR960402768T patent/GR3022356T3/el unknown
-
2001
- 2001-05-31 GR GR20010400060T patent/GR3035957T3/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003514858A (ja) * | 1999-11-24 | 2003-04-22 | アベンテイス・フアルマ・ソシエテ・アノニム | リルゾールおよびギャバペンチンの組み合わせ剤ならびに医薬としてのその使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08507507A (ja) | 神経−aidsの治療におけるリルゾールの適応 | |
RU2221563C2 (ru) | Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона | |
JP2713384B2 (ja) | 2‐アミノ‐6‐(トリフルオロメトキシ)‐ベンゾチアゾール(リルゾール)の運動ニューロン疾患の処置を意図した医薬を得るための使用 | |
JP2002511866A (ja) | 神経変性疾患治療のためのバニロイドレセプター複合体のアンタゴニストまたは部分的アゴニストの使用 | |
KR20040018380A (ko) | 피렌제핀 안약 겔제 | |
US11324692B2 (en) | Method to prepare pharmaceutical compositions of suggamadex | |
TWI260224B (en) | Pharmaceutical compositions for the treatment of tumor diseases | |
JP4637359B2 (ja) | ニセルゴリンの新規な治療的応用 | |
EP0471388B1 (de) | Mittel zur Behandlung der Herzinsuffizienz | |
JPS58189114A (ja) | 抗潰瘍剤 | |
US6432992B1 (en) | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy | |
GB2083749A (en) | Drug combination comprising ambroxol and an antibiotic for the treatment of infectious diseases of the respiratory tract | |
PT1470818E (pt) | Utilização de derivados de fenotiazina piperazina no fabrico de um medicamento com efeitos neuroprotectores e/ou neurotróficos no cns e/ou pns | |
AU628114B2 (en) | Pharmaceutical composition for ophthalmic use comprising a water soluble acid addition salt of ibopamine | |
JP4637360B2 (ja) | 1,6−ジメチル−8ベータ−ヒドロキシメチル−10アルファ−メトキシエルゴリンの新規な治療使用 | |
EP3932391A1 (en) | Method to prepare pharmaceutical compositions | |
WO2024033946A1 (en) | Compositions and use in methods for treating a cognitive deficit | |
JP4848117B2 (ja) | 副腎脳白質ジストロフィーを予防および治療するためのリルゾールもしくはその塩の使用 | |
GB2205097A (en) | Pharmaceutical preparations with cholinergic potentiating effect | |
WO2015105064A1 (ja) | 網膜疾患の予防又は治療のための医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040629 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040706 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070723 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080723 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080723 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090723 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090723 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100723 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110723 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110723 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120723 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120723 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130723 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |